Search Page

1

Cite

Share

What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia.

Banerjee S, Samsi K, Petrie CD, Alvir J, Treglia M, Schwam EM, del Valle M. Banerjee S, et al. Among authors: schwam em. Int J Geriatr Psychiatry. 2009 Jan;24(1):15-24. doi: 10.1002/gps.2090. Int J Geriatr Psychiatry. 2009. PMID: 18727132 Review.

Cite

Share

2

Cite

Share

A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease.

Schwam EM, Nicholas T, Chew R, Billing CB, Davidson W, Ambrose D, Altstiel LD. Schwam EM, et al. Curr Alzheimer Res. 2014;11(5):413-21. doi: 10.2174/1567205011666140505100858. Curr Alzheimer Res. 2014. PMID: 24801218 Clinical Trial.

Cite

Share

3

Cite

Share

Health economics and the value of therapy in Alzheimer's disease.

Schwam EM, Abu-Shakra S, del Valle M, Townsend RJ, Carrillo MC, Fillit H. Schwam EM, et al. Alzheimers Dement. 2007 Jul;3(3):143-51. doi: 10.1016/j.jalz.2007.04.391. Alzheimers Dement. 2007. PMID: 19595929

Cite

Share

4

Cite

Share

Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials.

Winblad B, Black SE, Homma A, Schwam EM, Moline M, Xu Y, Perdomo CA, Swartz J, Albert K. Winblad B, et al. Among authors: schwam em. Curr Med Res Opin. 2009 Nov;25(11):2577-87. doi: 10.1185/03007990903236731. Curr Med Res Opin. 2009. PMID: 19735164

Cite

Share

5

Cite

Share

Economic evaluation of donepezil in moderate to severe Alzheimer disease.

Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam EM, Shah S, Mastey V; Donepezil MSAD Study Investigators Group. Feldman H, et al. Among authors: schwam em. Neurology. 2004 Aug 24;63(4):644-50. doi: 10.1212/01.wnl.0000134663.79663.6e. Neurology. 2004. PMID: 15326236 Clinical Trial.

Cite

Share

6

Cite

Share

Defining treatment response to donepezil in Alzheimer's disease: responder analysis of patient-level data from randomized, placebo-controlled studies.

Burns A, Yeates A, Akintade L, Del Valle M, Zhang RY, Schwam EM, Perdomo CA. Burns A, et al. Among authors: schwam em. Drugs Aging. 2008;25(8):707-14. doi: 10.2165/00002512-200825080-00007. Drugs Aging. 2008. PMID: 18665662

Cite

Share

7

Cite

Share

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.

Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM; Donepezil MSAD Study Investigators Group. Feldman H, et al. Among authors: schwam em. Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69. doi: 10.1002/gps.1325. Int J Geriatr Psychiatry. 2005. PMID: 15920715 Clinical Trial.

Cite

Share

8

Cite

Share

Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: study with intravenous midazolam.

Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, Schwam EM, Siegel JL. Chernik DA, et al. Among authors: schwam em. J Clin Psychopharmacol. 1990 Aug;10(4):244-51. J Clin Psychopharmacol. 1990. PMID: 2286697 Clinical Trial.

Cite

Share

9

Cite

Share

Phase II crossover trial of varenicline in mild-to-moderate Alzheimer's disease.

Kim SY, Choi SH, Rollema H, Schwam EM, McRae T, Dubrava S, Jacobsen J. Kim SY, et al. Among authors: schwam em. Dement Geriatr Cogn Disord. 2014;37(3-4):232-45. doi: 10.1159/000355373. Epub 2013 Nov 14. Dement Geriatr Cogn Disord. 2014. PMID: 24247022 Clinical Trial.

Cite

Share

10

Cite

Share

Intravenous flumazenil following acute and repeated exposure to lorazepam in healthy volunteers: antagonism and precipitated withdrawal.

Griffiths RR, Evans SM, Guarino JJ, Roache JD, Furman WR, Liebson I, Schwam EM. Griffiths RR, et al. Among authors: schwam em. J Pharmacol Exp Ther. 1993 Jun;265(3):1163-74. J Pharmacol Exp Ther. 1993. PMID: 8510001 Clinical Trial.

Cite

Share